Skin involvement is a late complication that rarely occurs in ovarian cancer patients. This event invariably carries a bad prognosis in the course of an advanced stage ovarian carcinoma which is usually of the conventional serous type. Micropapillary serous carcinoma (MPSC) was recently recognized as a distinct neoplasm that seems to be less aggressive than conventional serous ovarian carcinoma. Indeed, a few cases of stage IV MPSC have been reported. Herein, we describe an unusual case of ovarian invasive MPSC occurring in a young woman, particularly by its mode of presentation as multiple subcutaneous nodules that were subsequently diagnosed as metastatic lesions. This case demonstrates the potential of MPSC for aggressive clinical behaviour.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-007-0519-xDOI Listing

Publication Analysis

Top Keywords

ovarian invasive
8
micropapillary serous
8
serous carcinoma
8
ovarian carcinoma
8
conventional serous
8
ovarian
5
skin metastases
4
metastases revealing
4
revealing bilateral
4
bilateral ovarian
4

Similar Publications

Primary Ovarian Lymphoma Treated with Da Vinci Robotic-Assisted Laparoscopy: A Rare Malignant Tumor of the Ovary.

J Minim Invasive Gynecol

December 2024

Department of Gynecology, Center for Reproductive Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China. Electronic address:

View Article and Find Full Text PDF

LPCAT3 regulates the proliferation and metastasis of serous ovarian cancer by modulating arachidonic acid.

Transl Oncol

December 2024

Laboratory of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. Electronic address:

Background: Lysophosphatidylcholine acyltransferase 3 (LPCAT3) promotes ferroptosis through the incorporating polyunsaturated fatty acids into membrane phospholipids, however, its role in serous ovarian cancer remains unclear. Here explored cancer proliferation and metastasis after modulating LPCAP3.

Methods: LPCAT3 protein in ovarian cancer tissues was detected using bioinformatic and immunohistoche mical assays.

View Article and Find Full Text PDF

LncRNA DNM1P35 sponges hsa-mir-326 to promote ovarian cancer progression.

Sci Rep

December 2024

Department of Gynaecology, The Affiliated Wuxi People's Hospital of Nanjing Medical University/Wuxi Medical Center, Nanjing Medical University/Wuxi People's Hospital, 299 Qingyang Road, Wuxi, 214023, Jiangsu, China.

Long non-coding RNAs (lncRNAs) have emerged as crucial regulators in cancer progression. We found lncRNA DNM1P35 is elevated in ovarian tumors compared to normal tissues, and demonstrated that lncRNA DNM1P35 promoted cancer cell proliferation, migration and invasion in SK-OV-3 and OVCAR-3 cell lines. Furthermore, lncRNA DNM1P35 also facilitated the epithelial-mesenchymal transition (EMT) of ovarian cancer cells.

View Article and Find Full Text PDF

Background: The dysregulation of ribosome biogenesis has been extensively identified in various cancers, making it emerge as a hallmark of malignant cells. This highlights the potential of targeting ribosome biogenesis as an effective approach for treating cancer patients. Although chemotherapy drugs including doxorubicin and cisplatin often target ribosome biogenesis to induce DNA damage or inhibit tumor cell proliferation, they are associated with significant side effects.

View Article and Find Full Text PDF

Introduction: Mucinous appendiceal neoplasms are unique tumors in which >50 % of the tumor volume is composed of extracellular mucin. They may present as an unruptured mucin-filled appendix or, more commonly, with peritoneal metastases after rupture or transmural invasion of the primary tumor. This case report describes a case of presumed ovarian malignancy with final pathologic diagnosis of low grade appendiceal mucinous neoplasm.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!